Jonathan S. Wolin - 11 Dec 2025 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Role
Chief of Staff, Chief Compliance Officer & General Counsel
Signature
/s/ Jonathan S. Wolin
Issuer symbol
JAGX
Transactions as of
11 Dec 2025
Net transactions value
$0
Form type
4
Filing time
21 Jan 2026, 16:30:27 UTC
Previous filing
26 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wolin Jonathan S. Chief of Staff, Chief Compliance Officer & General Counsel C/O JAGUAR HEALTH, INC., 200 PINE ST., STE 400, SAN FRANCISCO /s/ Jonathan S. Wolin 21 Jan 2026 0001787587

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAGX Common Stock Award $0 +11,740 +5929% $0.000000 11,938 11 Dec 2025 Direct F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAGX Stock Option (right to buy) Award $0 +11,740 $0.000000 11,740 11 Dec 2025 Common Stock 11,740 $1.44 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Granted pursuant to the issuer's 2014 Stock Incentive Plan.
F2 The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
F3 Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.
F4 On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split"). Upon effectiveness of the Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.
F5 The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the executive remains employed by the issuer.

Remarks:

Chief of Staff, Chief Compliance Officer & General Counsel